Phase 1 × Lymphoma, Follicular × Dermatologic × Clear all
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

Phase 1 Recruiting
46 enrolled
NCT00641381 2025-05-01

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
25 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Stanford University

Phase 1 Terminated
3 enrolled 5 charts
NCT01523223 2023-11-22

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Stanford University

Phase 1 Completed
16 enrolled
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT00049712 2019-12-13

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

University of Wisconsin, Madison

Phase 1 Completed
NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Swiss Cancer Institute

Phase 1 Completed
18 enrolled
NCT00005639 2019-01-11

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
34 enrolled
NCT00005092 2018-10-26

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
7 enrolled
NCT01484015 2018-07-18

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Wake Forest University Health Sciences

Phase 1 Completed
70 enrolled
NCT01129193 2018-06-04

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
44 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00509691 2017-05-09

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

University of Louisville

Phase 1 Completed
20 enrolled
NCT00047164 2016-09-26

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
89 enrolled
NCT00004239 2016-07-04

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Alliance for Clinical Trials in Oncology

Phase 1 Terminated
10 enrolled
NCT00293488 2016-06-23

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

Progen Pharmaceuticals

Phase 1 Completed
20 enrolled
NCT01748721 2016-01-08

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Morphotek

Phase 1 Completed
27 enrolled
NCT01658319 2015-08-13

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
20 enrolled
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT00045500 2015-04-30

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
NCT00002765 2015-04-29

Immunotoxin in Treating Patients With Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
NCT00003993 2015-04-29

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00019344 2015-04-29

Flavopiridol in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00004258 2014-09-17

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Indiana University

Phase 1 Completed
40 enrolled
NCT00003107 2014-09-10

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Indiana University

Phase 1 Completed
NCT00521261 2014-03-05

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00499811 2014-02-24

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00769288 2014-01-07

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
NCT00769613 2013-12-18

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
NCT00293345 2013-09-30

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00023816 2013-09-20

Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
NCT00324597 2013-09-17

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
18 enrolled
NCT00996359 2013-09-17

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Rutgers, The State University of New Jersey

Phase 1 Terminated
4 enrolled
NCT00006340 2013-07-26

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Boston Medical Center

Phase 1 Completed
NCT00025129 2013-07-18

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
NCT00049699 2013-07-18

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed